Literature DB >> 18264139

Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer.

W M Grady1, R K Parkin, P S Mitchell, J H Lee, Y-H Kim, K D Tsuchiya, M K Washington, C Paraskeva, J K V Willson, A M Kaz, E M Kroh, A Allen, B R Fritz, S D Markowitz, M Tewari.   

Abstract

MicroRNAs are small, non-coding RNAs that influence gene regulatory networks by post-transcriptional regulation of specific messenger RNA targets. MicroRNA expression is dysregulated in human malignancies, frequently leading to loss of expression of certain microRNAs. We report that expression of hsa-miR-342, a microRNA encoded in an intron of the gene EVL, is commonly suppressed in human colorectal cancer. The expression of hsa-miR-342 is coordinated with that of EVL and our results indicate that the mechanism of silencing is CpG island methylation upstream of EVL. We found methylation at the EVL/hsa-miR-342 locus in 86% of colorectal adenocarcinomas and in 67% of adenomas, indicating that it is an early event in colorectal carcinogenesis. In addition, we observed a higher frequency of methylation (56%) in histologically normal colorectal mucosa from individuals with concurrent cancer compared to mucosa from individuals without colorectal cancer (12%), suggesting the existence of a 'field defect' involving methylated EVL/hsa-miR-342. Furthermore, reconstitution of hsa-miR-342 in the colorectal cancer cell line HT-29 induced apoptosis, suggesting that this microRNA could function as a proapoptotic tumor suppressor. In aggregate, these results support a novel mechanism for silencing intronic microRNAs in cancer by epigenetic alterations of cognate host genes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18264139     DOI: 10.1038/onc.2008.10

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  124 in total

Review 1.  The role of microRNAs in colorectal cancer.

Authors:  Aaron J Schetter; Hirokazu Okayama; Curtis C Harris
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

Review 2.  Epigenetics and colorectal cancer.

Authors:  Victoria Valinluck Lao; William M Grady
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-10-18       Impact factor: 46.802

3.  miR-342-3p targets RAP2B to suppress proliferation and invasion of non-small cell lung cancer cells.

Authors:  Xiao Xie; Hongtao Liu; Mingsong Wang; Fangbao Ding; Haibo Xiao; Fengqing Hu; Rui Hu; Ju Mei
Journal:  Tumour Biol       Date:  2015-02-09

4.  Bioinformatics analyses of significant prognostic risk markers for thyroid papillary carcinoma.

Authors:  Xiao-Shan Min; Peng Huang; Xu Liu; Chao Dong; Xiao-Lin Jiang; Zheng-Tai Yuan; Lin-Feng Mao; Shi Chang
Journal:  Tumour Biol       Date:  2015-04-24

Review 5.  The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma.

Authors:  Muhammad Nauman Aftab; Marcel E Dinger; Ranjan J Perera
Journal:  Arch Biochem Biophys       Date:  2014-07-24       Impact factor: 4.013

6.  The role of promoter methylation in Epstein-Barr virus (EBV) microRNA expression in EBV-infected B cell lines.

Authors:  Do Nyun Kim; Yoon Jae Song; Suk Kyeong Lee
Journal:  Exp Mol Med       Date:  2011-07-30       Impact factor: 8.718

Review 7.  MicroRNA: a connecting road between apoptosis and cholesterol metabolism.

Authors:  Yogita K Adlakha; Neeru Saini
Journal:  Tumour Biol       Date:  2016-04-22

Review 8.  The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening.

Authors:  William M Grady; Sanford D Markowitz
Journal:  Dig Dis Sci       Date:  2014-12-10       Impact factor: 3.199

9.  hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations.

Authors:  F Wang; X Xue; J Wei; Y An; J Yao; H Cai; J Wu; C Dai; Z Qian; Z Xu; Y Miao
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

10.  MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.

Authors:  Aoife J Lowery; Nicola Miller; Amanda Devaney; Roisin E McNeill; Pamela A Davoren; Christophe Lemetre; Vladimir Benes; Sabine Schmidt; Jonathon Blake; Graham Ball; Michael J Kerin
Journal:  Breast Cancer Res       Date:  2009-05-11       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.